Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Mvasi™ (bevacizumab-awwb) – New biosimilar approval
September 14, 2017 – The FDA approved Mvasi (bevacizumab-awwb), Amgen’s biosimilar to Genentech’s Avastin® (bevacizumab), for the treatment of multiple types of cancer.
